Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer.

de Lange NM, Ezendam NPM, Kwon JS, Vandenput I, Mirchandani D, Amant F, van der Putten LJM, Pijnenborg JMA.

Curr Oncol. 2019 Apr;26(2):e226-e232. doi: 10.3747/co.26.4655. Epub 2019 Apr 1.

2.

Opportunistic salpingectomy in women undergoing hysterectomy: Results from the HYSTUB randomised controlled trial.

Van Lieshout LAM, Pijlman B, Vos MC, de Groot MJM, Houterman S, Coppus SFPJ, Harmsen MG, Vandenput I, Piek JMJ.

Maturitas. 2018 Jan;107:1-6. doi: 10.1016/j.maturitas.2017.09.012. Epub 2017 Oct 3.

PMID:
29169572
3.

PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study, pre-operative recognition of high risk endometrial carcinoma: a multicentre prospective cohort study.

Visser NC, Bulten J, van der Wurff AA, Boss EA, Bronkhorst CM, Feijen HW, Haartsen JE, van Herk HA, de Kievit IM, Klinkhamer PJ, Pijlman BM, Snijders MP, Vandenput I, Vos MC, de Wit PE, van de Poll-Franse LV, Massuger LF, Pijnenborg JM.

BMC Cancer. 2015 Jun 30;15:487. doi: 10.1186/s12885-015-1487-3.

4.

Synchronous ovarian and endometrial cancer--an international multicenter case-control study.

Heitz F, Amant F, Fotopoulou C, Battista MJ, Wimberger P, Traut A, Fisseler-Eckhoff A, Harter P, Vandenput I, Sehouli J, Schmidt M, Kimmig R, du Bois R, du Bois A.

Int J Gynecol Cancer. 2014 Jan;24(1):54-60. doi: 10.1097/IGC.0000000000000019.

PMID:
24300466
5.

Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.

Trovik J, Wik E, Werner HM, Krakstad C, Helland H, Vandenput I, Njolstad TS, Stefansson IM, Marcickiewicz J, Tingulstad S, Staff AC; MoMaTEC study group, Amant F, Akslen LA, Salvesen HB.

Eur J Cancer. 2013 Nov;49(16):3431-41. doi: 10.1016/j.ejca.2013.06.016. Epub 2013 Aug 8.

6.

High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.

Garcia-Dios DA, Lambrechts D, Coenegrachts L, Vandenput I, Capoen A, Webb PM, Ferguson K; ANECS, Akslen LA, Claes B, Vergote I, Moerman P, Van Robays J, Marcickiewicz J, Salvesen HB, Spurdle AB, Amant F.

Gynecol Oncol. 2013 Feb;128(2):327-34. doi: 10.1016/j.ygyno.2012.11.037. Epub 2012 Dec 4.

PMID:
23219661
7.

Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.

Vandenput I, Vergote I, Neven P, Amant F.

Int J Gynecol Cancer. 2012 May;22(4):617-22. doi: 10.1097/IGC.0b013e31824a3385.

PMID:
22426408
8.

Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer.

van der Horst PH, Wang Y, Vandenput I, Kühne LC, Ewing PC, van Ijcken WF, van der Zee M, Amant F, Burger CW, Blok LJ.

PLoS One. 2012;7(1):e30840. doi: 10.1371/journal.pone.0030840. Epub 2012 Jan 25.

9.

Pitfall in the diagnosis of endometrial cancer: case report of an endometrioid adenocarcinoma arising from uterine adenomyosis.

Boes AS, Tousseyn T, Vandenput I, Timmerman D, Vergote I, Moerman P, Amant F.

Eur J Gynaecol Oncol. 2011;32(4):431-4.

PMID:
21941970
10.

Expression of ERCC1, p53, and class III β-tubulin do not reveal chemoresistance in endometrial cancer: results from an immunohistochemical study.

Vandenput I, Capoen A, Coenegrachts L, Verbist G, Moerman P, Vergote I, Amant F.

Int J Gynecol Cancer. 2011 Aug;21(6):1071-7. doi: 10.1097/IGC.0b013e318218f28b.

PMID:
21792013
11.

Evolution in endometrial cancer: evidence from an immunohistochemical study.

Vandenput I, Trovik J, Leunen K, Wik E, Stefansson I, Akslen L, Moerman P, Vergote I, Salvesen H, Amant F.

Int J Gynecol Cancer. 2011 Feb;21(2):316-22. doi: 10.1097/IGC.0b013e31820575f5.

PMID:
21734474
12.

The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study.

Vandenput I, Trovik J, Vergote I, Moerman P, Leunen K, Berteloot P, Neven P, Salvesen H, Amant F.

Int J Gynecol Cancer. 2011 Feb;21(2):332-6. doi: 10.1097/IGC.0b013e3182094ded.

PMID:
21270614
13.

Kit gene in endometrial carcinoma: an immunohistochemical and mutational analysis.

Vandenput I, Debiec-Rychter M, Capoen A, Verbist G, Vergote I, Moerman P, Amant F.

Int J Gynecol Cancer. 2011 Feb;21(2):203-5. doi: 10.1097/IGC.0b013e3182055c94.

PMID:
21270602
14.

Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer.

Trovik J, Wik E, Stefansson IM, Marcickiewicz J, Tingulstad S, Staff AC, Njolstad TS; MoMaTec Study Group, Vandenput I, Amant F, Akslen LA, Salvesen HB.

Clin Cancer Res. 2011 May 15;17(10):3368-77. doi: 10.1158/1078-0432.CCR-10-2412. Epub 2011 Jan 17.

15.

Clinicopathologic study in uterine cancer.

Vandenput I.

Facts Views Vis Obgyn. 2011;3(3):189-202.

16.

The use of lymph vessel markers to predict endometrial cancer outcome.

Vandenput I, Vanhove T, Calster BV, Gorp TV, Moerman P, Verbist G, Vergote I, Amant F.

Int J Gynecol Cancer. 2010 Apr;20(3):363-7. doi: 10.1111/IGC.0b013e3181d4a0b9.

PMID:
20375798
17.

Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.

Vandenput I, Vergote I, Leunen K, Berteloot P, Neven P, Amant F.

Int J Gynecol Cancer. 2009 Aug;19(6):1147-51. doi: 10.1111/IGC.0b013e3181ad3dcb.

PMID:
19820384
18.
19.

Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?

Vandenput I, Van Calster B, Capoen A, Leunen K, Berteloot P, Neven P, Moerman P, Vergote I, Amant F.

Br J Cancer. 2009 Jul 21;101(2):244-9. doi: 10.1038/sj.bjc.6605157. Epub 2009 Jun 30.

20.

Residual tumor after neoadjuvant chemotherapy and interval debulking surgery for advanced endometrial cancer.

Amant F, Despierre E, Vandenput I.

Gynecol Oncol. 2009 Aug;114(2):370; author reply 370. doi: 10.1016/j.ygyno.2009.03.024. Epub 2009 Apr 26. No abstract available.

PMID:
19398127
21.

Limited clinical benefit from trastuzumab in recurrent endometrial cancer: two case reports.

Vandenput I, Vanden Bempt I, Leunen K, Neven P, Berteloot P, Moerman P, Vergote I, Amant F.

Gynecol Obstet Invest. 2009;67(1):46-8. doi: 10.1159/000161568. Epub 2008 Oct 9.

PMID:
18843183
22.

Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer.

Vandenput I, Amant F, Neven P, Berteloot P, Leunen K, Vergote I.

Int J Gynecol Cancer. 2007 Jan-Feb;17(1):83-7.

PMID:
17291236
23.

Aromatase inhibitors in premenopausal women: the need for proper contraceptive counseling.

Vandenput I, Vergote I, Amant F, Neven P, Paridaens R, Christiaens MR.

Breast J. 2006 Sep-Oct;12(5):507-8. No abstract available.

PMID:
16958981
24.

Endometrial carcinosarcoma with osteoclast-like giant cells.

Amant F, Vandenput I, Van Gorp T, Vergote I, Moerman P.

Eur J Gynaecol Oncol. 2006;27(1):92-4.

PMID:
16550981
25.

Peritoneal recurrences might be less common in advanced stage serous borderline ovarian tumors that were treated by laparotomy.

Vandenput I, Amant F, Vergote I.

Gynecol Oncol. 2005 Sep;98(3):523; author reply 524-5. No abstract available.

PMID:
16054202

Supplemental Content

Loading ...
Support Center